Pharmacokinetic study shows superior bioavailability for resveratrol using Gencor’s LipiSperse technology

March 10, 2021
Sebastian Krawiec

Gencor announced the results of a pharmacokinetic study on trans-resveratrol bioavailability in humans using VeriSperse, a proprietary cold water dispersible resveratrol powder that uses Gencor’s patented LipiSperse technology.

Gencor (Irvine, CA) announced the results of a pharmacokinetic study on trans-resveratrol bioavailability in humans using VeriSperse, a proprietary cold water dispersible resveratrol powder that uses Gencor’s patented LipiSperse technology. In the single-dose, double-blind, randomized study, healthy adults were randomized to receive either 75 mg of VeriSperse, 150 mg of VeriSperse, or 150 mg of resveratrol without the LipiSperse delivery complex.

Results showed that the 150 mg dose of VeriSperse showed a two-fold increase in absorption and a three-sold increase in C-max of trans-resveratrol conjugates compared to the 150 mg of resveratrol without the LipiSperse delivery complex. However, there was no statistical difference between the 75 mg of VeriSperse and the 150 mg of standard resveratrol.

“Like other polyphenols, the oral intake of resveratrol has a relatively low bioavailability,” said Chase Shyroc, vice president of sales and business development for Gencor, in a press release. “By using the LipiSperse delivery system, we’ve seen significant increase in VeriSperse’s bioavailability and efficacy along with the benefit of improved functionality.”

The study was funded by Pharmako Biotechnologies, Gencor’s sister company.